Ovarian cancer relapse: From the latest scientific evidence to the best practice.


University Campus Bio Medico of Rome, Department of Obstetrics and Gynecology, Via Álvaro del Portillo, 200, 00128 Rome, Italy. Electronic address: [Email]


Ovarian cancer (OC) is the fifth most common cause of cancer death in women worldwide. Despite treatment options have continued to improve in recent years, the recurrence rate is still high; in fact around 80% of patients relapses within 18 months. Recently, the scientific landscape is agree in asserting that the ovarian cancer is not a single disease but the outcome of patients depends from the molecular and biological characterization of tumor tissue. In this scenario, molecular targeted therapy given alone or in combination with chemotherapy is showing significant results. We review the different options for the treatment of ovarian cancer recurrence, including the role of surgery, in order to try outlining a possible treatment algorithm evaluating the recent scientific literature and the most important trials.


Chemotherapy,Ovarian cancer,Parp inhibitors,Recurrence,